Masaki Shimizu1, Natsumi Inoue2, Mondo Kuroda2, Hitoshi Irabu2, Maiko Takakura2, Hisashi Kaneda3, Naotoshi Sugimoto4, Kazuhide Ohta5, Akihiro Yachie2. 1. Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Japan. shimizum@staff.kanazawa-u.ac.jp. 2. Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Japan. 3. Department of Pediatrics, Komatsu Municipal Hospital, Komatsu, Japan. 4. Department of Physiology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan. 5. Department of Pediatrics, Kanazawa Medical Center, Kanazawa, Japan.
Abstract
OBJECTIVES: To investigate the diagnostic value of serum ferritin levels as a marker of disease activity and the development of encephalopathy in hemolytic uremic syndrome (HUS) induced by enterohemorrhagic Escherichia coli. METHODS: Twenty patients with HUS were studied. Serum ferritin levels were compared with clinical features and serum soluble tumor necrosis factor receptor (sTNFR) I and sTNFRII levels. Serum sTNFRI and sTNFRII levels were quantified by enzyme-linked immunosorbent assays. RESULTS: Serum ferritin levels were significantly elevated at the time of the diagnosis of HUS. Serum ferritin levels were significantly elevated in patients with encephalopathy compared to patients without encephalopathy. HUS patients with serum ferritin levels of >687.5 ng/ml were at high risk of encephalopathy. Serum ferritin levels were significantly positively correlated with serum sTNFRI and sTNFRII levels. CONCLUSIONS: Serum ferritin levels are a promising indicator of the development of encephalopathy in HUS.
OBJECTIVES: To investigate the diagnostic value of serum ferritin levels as a marker of disease activity and the development of encephalopathy in hemolytic uremic syndrome (HUS) induced by enterohemorrhagic Escherichia coli. METHODS: Twenty patients with HUS were studied. Serum ferritin levels were compared with clinical features and serum soluble tumornecrosis factor receptor (sTNFR) I and sTNFRII levels. Serum sTNFRI and sTNFRII levels were quantified by enzyme-linked immunosorbent assays. RESULTS: Serum ferritin levels were significantly elevated at the time of the diagnosis of HUS. Serum ferritin levels were significantly elevated in patients with encephalopathy compared to patients without encephalopathy. HUSpatients with serum ferritin levels of >687.5 ng/ml were at high risk of encephalopathy. Serum ferritin levels were significantly positively correlated with serum sTNFRI and sTNFRII levels. CONCLUSIONS: Serum ferritin levels are a promising indicator of the development of encephalopathy in HUS.